TIGIT Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 18+ Companies and 20+ Drugs

TIGIT inhibitors present a strong market opportunity, with numerous global players advancing in immuno-oncology. Key opportunities lie in developing and commercializing emerging therapies, especially ...

CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and ...

The CTLA-4 inhibitors market offers promising opportunities in cancer immunotherapy, with over 40 companies developing 50+ drugs globally. Key opportunities include leveraging synergistic combinations ...
Business Wire

Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-catenin TCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with ...

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 ...

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market to Hit $29.9B by 2033 on Cancer, Aging Demographics – SRI

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...